Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

CHIEF FINANCIAL OFFICER

PRINCIPAL ACCOUNTING OFFICER

CHIEF COMMERCIAL OFFICER

CHIEF EXECUTIVE OFFICER

CHIEF PEOPLE OFFICER

PRESIDENT, R & D

EVP AND CHIEF LEGAL OFFICER

CHIEF TECHNICAL OPERATIONS

CHIEF SCIENTIFIC OFFICER

CHIEF MEDICAL OFFICER

CHIEF OPERATING OFFICER

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and Fisogatinib. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in th...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-28	Premium	acquired	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-03-28	Premium	sold	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-03-20	Premium	sold	Premium	Premium	Premium	-
2024-03-20	Premium	acquired	Premium	Premium	Premium	-
2024-03-15	Premium	acquired	Premium	Premium	Premium	PRINCIPAL ACCOUNTING OFFICER
2024-03-15	Premium	sold	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-03-15	Premium	acquired	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-03-15	Premium	sold	Premium	Premium	Premium	PRINCIPAL ACCOUNTING OFFICER
2024-03-13	Premium	acquired	Premium	Premium	Premium	CHIEF COMMERCIAL OFFICER
2024-03-13	Premium	sold	Premium	Premium	Premium	CHIEF COMMERCIAL OFFICER
2024-03-07	Premium	sold	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2024-03-07	Premium	sold	Premium	Premium	Premium	-
2024-03-07	Premium	sold	Premium	Premium	Premium	PRINCIPAL ACCOUNTING OFFICER
2024-03-07	Premium	sold	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2024-03-07	Premium	sold	Premium	Premium	Premium	CHIEF PEOPLE OFFICER
2024-03-07	Premium	sold	Premium	Premium	Premium	PRESIDENT, R & D
2024-03-07	Premium	sold	Premium	Premium	Premium	EVP AND CHIEF LEGAL OFFICER
2024-03-07	Premium	sold	Premium	Premium	Premium	CHIEF TECHNICAL OPERATIONS
2024-03-07	Premium	sold	Premium	Premium	Premium	CHIEF COMMERCIAL OFFICER
2024-03-07	Premium	sold	Premium	Premium	Premium	CHIEF SCIENTIFIC OFFICER
2024-03-07	Premium	sold	Premium	Premium	Premium	CHIEF MEDICAL OFFICER
2024-03-07	Premium	sold	Premium	Premium	Premium	CHIEF OPERATING OFFICER
2024-03-04	Premium	sold	Premium	Premium	Premium	CHIEF TECHNICAL OPERATIONS
2024-03-01	Premium	acquired	Premium	Premium	Premium	CHIEF OPERATING OFFICER
2024-03-01	Premium	acquired	Premium	Premium	Premium	EVP AND CHIEF LEGAL OFFICER

BPMC - Blueprint Medicines Corp Stock Price, Fair Value and News

Latest Insider Trading transactions for BPMC